Stock Events

Stock Events

Enzolytics 

$0
46
+$0+33.33% Thursday 19:21

Statistics

Day High
0
Day Low
0
52W High
0
52W Low
0
Volume
607,500
Avg. Volume
8,906,266
Mkt Cap
1.93M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
May 12
$150
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

30JunExpected
Q3 2016
Q4 2016
Q1 2017
Q2 2017
Q3 2017
Q4 2017
Q1 2018
-0
-0
0
0
Expected EPS
N/A
Actual EPS
-0.0008

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-788,000Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ENZC. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that develops and markets treatments for HIV/AIDS, liver diseases, cancer, and inflammatory and respiratory diseases, competing directly with Enzolytics' focus on infectious diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is involved in the discovery, development, and commercialization of medicines for treating cancer, eye diseases, and infectious diseases, making it a direct competitor in the biotech space.
Moderna
MRNA
Mkt Cap10.61B
Moderna is known for its mRNA technology used in vaccines, directly competing with Enzolytics' efforts in developing treatments for infectious diseases, including HIV and COVID-19.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech SE operates in the biotechnology industry focusing on patient-specific immunotherapies for cancer and infectious diseases, competing with Enzolytics in the infectious disease sector.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical corporation with a broad portfolio, including vaccines and drugs for infectious diseases, directly competing with Enzolytics' therapeutic and vaccine development.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments and vaccines for infectious diseases, posing competition to Enzolytics' similar focus areas.
Novavax
NVAX
Mkt Cap1.36B
Novavax is a biotechnology company that develops vaccines for infectious diseases, including COVID-19, directly competing with Enzolytics' research and development in infectious disease vaccines.
Arbutus Biopharma
ABUS
Mkt Cap906.73M
Arbutus Biopharma Corporation focuses on discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection, a direct competitor in the viral infection treatment space.
IN8bio
INAB
Mkt Cap8.85M
IN8bio, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for infectious diseases and cancer, making it a competitor in the biotech and infectious disease market.

About

Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.
Show more...
CEO
Mr. Harry H. Zhabilov Jr., BSc, McS Science
Employees
1
Country
US
ISIN
US2941121079

Listings

OTC Link
US
ENZC

0 Comments

Share your thoughts

FAQ

What is Enzolytics stock price today?▼
The current price of ENZC is $0 USD — it has increased by +33.33% in the past 24 hours. Watch Enzolytics stock price performance more closely on the chart.
What is Enzolytics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Enzolytics stocks are traded under the ticker ENZC.
Is Enzolytics stock price growing?▼
ENZC stock has risen by +33.33% compared to the previous week, the month change is a -11.11% fall, over the last year Enzolytics has showed a -42.86% decrease.
What is Enzolytics market cap?▼
Today Enzolytics has the market capitalization of 1.93M
What were Enzolytics earnings last quarter?▼
ENZC earnings for the last quarter are -0 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Enzolytics revenue for the last year?▼
Enzolytics revenue for the last year amounts to 0 USD.
What is Enzolytics net income for the last year?▼
ENZC net income for the last year is -788,000 USD.
Does Enzolytics pay dividends?▼
Yes, ENZC dividends are paid en. The last dividend per share was 150 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Enzolytics have?▼
As of April 03, 2026, the company has 1 employees.
In which sector is Enzolytics located?▼
Enzolytics operates in the Health Care sector.
When did Enzolytics complete a stock split?▼
The last stock split for Enzolytics was on February 07, 2013 with a ratio of 1:500.
Where is Enzolytics headquartered?▼
Enzolytics is headquartered in Plano, US.